Hinge Health Inc. Class A Common Stock vs T-Mobile Us Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while T-Mobile Us Inc trades at $158.34 (market cap $164.91B). The key difference: T-Mobile Us Inc is far larger — about 19.4× Hinge Health Inc. Class A Common Stock's market cap, and T-Mobile Us Inc pays a 3.04% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and T-Mobile Us Inc for 84 Days on average.
| HNGE | TMUS | |
|---|---|---|
Market Cap | $8.48B | $164.91B |
Volume | 879,799 | 5,684,850 |
Sector | Health | Media |
52-Week High | $105.14 | $230.06 |
52-Week Low | $31.17 | $148.58 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $8.10B | $281.53B |
Dividend Yield | — | 3.04% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
T-Mobile US (TMUS) trades at $157.79, up 3.9% with strong recent earnings beats but faces technical bearish signals. The company maintains robust fundamentals with $88.31B revenue (2025), 11.45% net margin, and attractive valuation ratios (P/E 16.08, EV/EBITDA 8.73). Recent developments include a 15% dividend hike and AI-powered 5G network enhancements, though debt levels remain elevated at $84.6B.
TMUS presents a compelling growth story with solid profitability and analyst support (81% buy rating, $221.75 target), but investors must weigh technical weakness against fundamental strength. Key risks include competitive pressures, macroeconomic uncertainty, and the company's substantial debt load in a rising rate environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →